
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
The author discusses the current pharmacopeial status of the acceptance limits and classifications of pharmaceutical residual solvents.
about 24 years ago
Contract Servicesabout 24 years ago
Major Changes Ahead for FDA




